Denny Lanfear, Coherus BioSciences CEO

FDA in­spec­tion of Chi­na-based site mak­ing Co­herus' po­ten­tial new can­cer drug ends with three ob­ser­va­tions

Af­ter Covid-re­lat­ed de­lays that forced the FDA to de­lay its Chi­na-based in­spec­tions, Co­herus Bio­Sciences said to­day that its Chi­na-based part­ner Jun­shi Bio­sciences has now suc­cess­ful­ly com­plet­ed the re­quired pre-ap­proval in­spec­tion for its PD-1 tori­pal­imab, which is be­ing made at a site in Chi­na, with three ob­ser­va­tions.

“The Com­pa­ny be­lieves that the three ob­ser­va­tions re­ceived at the close of the FDA in­spec­tion are read­i­ly ad­dress­able and, to­geth­er with Jun­shi Bio­sciences, plans to sub­mit the re­sponse to the FDA in ear­ly June,” Co­herus said in an SEC fil­ing. The com­pa­ny did not dis­close the ob­ser­va­tions, but Co­herus’ stock price $CHRS fell by al­most 8% on Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA